Innovating Novel Combination Therapies and Maximising Preclinical and Clinical Development to Improve Glioblastoma Targeting and Increase Investment Opportunities to Ultimately Bring Efficacious Therapies to Patients in Need
The glioblastoma drug development space has been energized by Merck’s acquisition of Modifi Bio last December. This landmark deal has sparked renewed hope in a field long challenged by limited investment and clinical breakthroughs.

Date and Time: Tuesday, 17 February 2026 at 08:30 – Thursday, 19 February 2026 at 17:30

Venue details: The Royal Sonesta Boston, 40 Edwin H Land Boulevard, Cambridge, Massachusetts, 02142, United States

Prices:
USD 2599.00 – USD 5097.00